Marginal zone lymphoma (MZL) comprises a group of indolent (slow growing) B-cell non-Hodgkin’s lymphomas (NHLs). With an annual incidence of approximately 7500 newly diagnosed patients in the United States,1 and approximately 19,000 new cases globally in 2020,2 MZL is the third most common B-cell NHL, accounting for approximately 8% of all NHL cases. MZL consists of 3 different subtypes: extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).3

Follicular lymphoma (FL) is a slow-growing or indolent form of NHL and is the most common type of indolent NHL, accounting for 20% to 30% of all NHL cases.4 In the United States, Japan, and EU, there are currently approximately 245,000 people living with FL, with approximately 31,000 new cases per year.2,5  While FL is usually considered to be incurable, patients often live with the disease for many years.

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. 2. Global Data 2016 NHL Model. 3. Marginal Zone Lymphoma. Lymphoma Research Foundation website. Accessed October 26, 2020. 4. Follicular Lymphoma. Lymphoma Research Foundation website. Accessed October 26, 2020. 5. Pharmacyclics Corporate Presentation. December 2014. Accessed October 29, 2020.

Learn how we’re bringing change
to indolent lymphoma and CLL